Raised CSF levels of P-tau and reduced levels of β-amyloid 1-42 are markers of the presence of Alzheimer pathology in the brains of Parkinson’s disease cases and predictors of their subsequent cognitive decline. Here, MAPT is linked to Parkinson disease.